Certain chronic neurologic disorders produce hyper-and -hypo-kinetic movement during the day, for examples levodopa-induced dyskinesia, multiple sclerosis and others. These progressive disorders are often accompanied by sleep disturbance at night.
Adamas is developing ADS-5102 with potential applications across a number of chronic neurologic disorders. We are focusing initial development on the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. The New Drug Application (NDA) supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of August 24, 2017. If approved, ADS-5102 will meet a significant unmet need, as the first and only medicine approved for dyskinesia in people with Parkinson’s disease.
We are also investigating ADS-5102 for the treatment of walking impairment in multiple sclerosis patients and considering developing it for other indications in Parkinson’s disease, post stroke walking impairment, and side effects induced by anti-psychotic drugs, such as tardive dyskinesia, akathesia and weight gain.